Introduction to "Immunotherapies for Multiple Myeloma"

Pharmaceuticals (Basel). 2020 Nov 17;13(11):396. doi: 10.3390/ph13110396.

Abstract

Multiple myeloma (MM) is the second most common hematological cancer after diffuse large B-cell lymphoma, accounting for about 10% of all blood cancers [...].

Publication types

  • Editorial